Central European Journal of Medicine

, Volume 3, Issue 1, pp 29–39 | Cite as

DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study

  • Aristotle Bamias
  • George Fountzilas
  • Michael Michael
  • Christos Konstantaras
  • Eleftheria Vrettou
  • Efstathios Eleftheriadis
  • Pavlos Papakostas
  • Konstantionos Papadimitriou
  • Nicholas Pavlidis
  • Nikos Xiros
  • Maria Bai
Research Article


There is a high risk of relapse after resection of gastric cancer. We studied the prognostic significance of the deleted colorectal cancer (DCC) gene and thymidylate synthase (TS) protein expression after resection of gastric cancer. Protein expression in the primary tumor of 146 patients with serosal and/or lymph node involvement was studied immunohistochemically by using anti-DCC and anti-TS monoclonal antibodies. DCC expression was found in 69.9%, while low TS staining intensity (0+,1+) and focal staining (<25% of tumor cells stained) were found in 44.6% and 33.8%, respectively. Overall survival (OS) was significantly longer in patients with DCC (p=0.014) negative tumors. TS expression was not an independent prognostic factor. Lack of DCC expression was associated with significantly longer cause-specific survival (CSS) (p=0.040) after curative resection. In conclusion, DCC expression is an independent prognostic factor in patients undergoing resection of gastric cancer while TS expression was not associated with the prognosis in our study.


DCC TS Gastric cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Alexander H.R., Kelsen D.P., Tepper J.E., Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA, (Eds.) Cancer. Principles and Practice of Oncology, Philadelphia, Lippincot-Raven Publishers, 1997, 1021–1053Google Scholar
  2. [2]
    Fuchs C.S., Mayer R.J., Gastric carcinoma., N. Engl. J. Med., 1995, 333, 32–41PubMedCrossRefGoogle Scholar
  3. [3]
    Kelsen D.P., Adjuvant and neoadjuvant therapy for gastric cancer., Semin. Oncol., 1996, 23, 379–389PubMedGoogle Scholar
  4. [4]
    Cho K.R., Fearon E.R., DCC: Linking tumor suppressor genes and altered cell surface interactions in cancer?, Eur. J. Cancer., 1995, 31A, 1055–1060PubMedCrossRefGoogle Scholar
  5. [5]
    Uchino S., Tsuda H., Noguchi M., Yokota J., Terada M., Saito T., et al., Frequent loss of heterozygosity at the DCC locus in gastric cancer., Cancer. Res., 1992, 52, 3099–3102PubMedGoogle Scholar
  6. [6]
    Fang D.C., Jass J.R., Wang D.X., Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer., J. Clin. Pathol., 1998, 51, 593–596PubMedCrossRefGoogle Scholar
  7. [7]
    Cropp C.S., Lidereau R., Campbell G., Champene M.H., Callahan R., Loss of heterozygosity on chromosome 17 and 18 in breast carcinoma: two additional regions identified., Proc. Natl. Acad. Sci. USA, 1990, 87, 7737–7741PubMedCrossRefGoogle Scholar
  8. [8]
    Gao X., Honn K.V., Grignon D., Sakr W., Chen Y.Q., Frequent loss of expression and loss of heterozygosity of putative tumor suppressor gene DCC in prostatic carcinomas., Cancer. Res., 1993, 53, 2723–2727PubMedGoogle Scholar
  9. [9]
    Peng H.Q., Bailey D., Bronson D., Goss P.D., Hong D., Loss of heterozygosity of tumor suppressor genes in testis cancer., Cancer. Res., 1995, 55, 2871–2875PubMedGoogle Scholar
  10. [10]
    Jen J., Kim H., Piantadosi S., Liu Z.F., Levitt R.C., Sistonen P., et al., Allelic loss of chromosome 18q and prognosis in colorectal cancer., N. Engl. J. Med., 1994, 331, 213–221PubMedCrossRefGoogle Scholar
  11. [11]
    O’Connell M.J, Schaid D.J., Ganju V., Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?, Cancer., 1992, 70, 1732–1739PubMedCrossRefGoogle Scholar
  12. [12]
    Watanabe T., Tsung-The W., Catalano P.J., Ueki T., Satriano R., Haller D.G., et al., Molecular predictors of survival after adjuvant chemotherapy for colon cancer., N. Engl. J. Med., 2001, 344, 1196–1206PubMedCrossRefGoogle Scholar
  13. [13]
    Shibata D., Reale M.A., Lavin P., Silverman M., Fearon E.R., Steele G., et al., The DCC protein and prognosis in colorectal cancer., N. Engl. J. Med., 1996, 335, 1727–1732PubMedCrossRefGoogle Scholar
  14. [14]
    Sun X.F., Rutten S., Zhang H., Nordenskjold B., Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma., J. Clin. Oncol., 1999, 17, 1745–1750PubMedGoogle Scholar
  15. [15]
    Candusso M.E., Luinetti O., Villani L., Alberizzi P., Klersy C., Fiocca R., et al., Loss of heterozygosity at 18q21 region in gastric cancer involves a number of cancer-related genes and correlates with stage and histology, but lacks independent prognostic value., J. Pathol. 2002, 197, 44–50PubMedCrossRefGoogle Scholar
  16. [16]
    Bamias A.T., Bai M.C., Agnantis N.J., Michael M.C., Alamanos Y.P., Stefanaki S.V., et al., Prognostic significance of the deleted in colorectal cancer (DCC) gene expression in high risk resected gastric carcinoma., Cancer. Investigation, 2003, 21, 333–340PubMedCrossRefGoogle Scholar
  17. [17]
    Pinedo H.M., Peters G.F.J., Fluorouracil: Biochemistry and pharmacology., J. Clin. Oncol., 1988, 6, 1653–1664PubMedGoogle Scholar
  18. [18]
    Aschele C., Debernardis D., Casazza S., Antonelli G., Tunesi G., Baldo C., et al., Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to Fluorouracil-based chemotherapy., J. Clin. Oncol., 1999, 17, 1760–1770PubMedGoogle Scholar
  19. [19]
    Lenz H.J., Hayashi K., Salonga D., Danenberg K.D., Danenberg P.V., Metzger R., et al., P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival., Clin. Cancer. Res., 1998, 4, 1243–1250PubMedGoogle Scholar
  20. [20]
    Boku N., Chin K., Hosokawa K., Ohtsu A., Tajiri H., Yoshida S., et al., Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-Fluorouracil and cis-Platinum., Clin. Cancer. Res., 1998, 4, 1469–1474PubMedGoogle Scholar
  21. [21]
    Pestalozzi B.C., Peterson H.F., Gelber R.D., Goldhirsch A., Gusterson B.A., Trihia H., et al., Prognostic importance of thymidylate synthase expression in early breast cancer., J. Clin. Oncol., 1997, 15, 1923–1931PubMedGoogle Scholar
  22. [22]
    Edler D., Kressner U., Ragnhammar P., Johnston P.G., Magnusson I., Glimelius B., et al., Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival., Clin. Cancer. Res., 2000, 6, 488–492PubMedGoogle Scholar
  23. [23]
    Johnston P.G., Fisher E.R., Rockette H.E., Fisher B., Wolmark N., Drake J.C., et al., The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer., J. Clin. Oncol., 1994, 12, 2640–2647PubMedGoogle Scholar
  24. [24]
    Allegra C.J., Parr A.L., Wold L.E., Mahoney M.R., Sargent D.J., Johnston P.G., et al., Investigation of the prognostic and predicitve value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer., J. Clin. Oncol., 2002, 20, 1735–1743PubMedCrossRefGoogle Scholar
  25. [25]
    Lenz H.J., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., et al., Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival., J. Clin. Oncol., 1996, 14, 1176–1182Google Scholar
  26. [26]
    Suda Y., Kuwashima Y., Tanaka Y., Uchida K., Akazawa S., Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-Fluoropyrimidines., Anticancer. Res., 1999, 19, 805–810PubMedGoogle Scholar
  27. [27]
    Choi J.H., Lim H.Y., Nam D.K., Kim H.S., Cho D.Y., Yi J.W., et al., Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection., Br. J. Cancer., 2001, 84, 186–192PubMedCrossRefGoogle Scholar
  28. [28]
    Kuniyashu T., Nakamura T., Tabuchi Y., Kuroda Y., Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody., Cancer., 1998, 83, 1300–1306CrossRefGoogle Scholar
  29. [29]
    Ishikawa Y., Tetsuro K., Otani Y., Watanabe M., Teramoto T., Kumai K., et al., Thymidylate synthetase and Dihydropyrimidine dehydrogenase levels in gastric cancer., Anticancer. Res., 1999, 19, 5635–5640PubMedGoogle Scholar
  30. [30]
    Pestalozzi B.C., McGinn C.J., Kinsella T.J., Increased thymidylate synthase protein levels are associated with proliferation but not cell cycle phase in asynchronous human cancer cells., Br. J. Cancer., 1995, 71, 1151–1157PubMedGoogle Scholar
  31. [31]
    Yonemura Y., Kimura H., Fushida S., Tugawa K., Nakai Y., Kaji M., et al., Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy., Cancer. 1993, 71, 2448–2453PubMedCrossRefGoogle Scholar
  32. [32]
    Kakeji Y., Maehara Y., Adachi Y., Baba H., Mori M., Furusawa M., et al., Proliferative activity as a prognostic factor in Bormann type 4 gastric carcinoma., Br. J. Cancer., 1994, 69, 749–753PubMedGoogle Scholar
  33. [33]
    Bai M., Vlachoniklis J., Agnantis N.J., Tsanou E., Dimou S., Nicolaides C., et al., Low expression of p27 protein combined with altered p53 and Rb/p16 status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas., Mod. Pathol. 2001, 14(11), 1105–1113PubMedCrossRefGoogle Scholar
  34. [34]
    Armitage P., Berry G., Statistical methods in medical research. Oxford, United Kingdom, Blackwell Scientific Publications, 1994Google Scholar
  35. [35]
    Kaplan E., Meier P., Nonparametric estimation from incomplete observations., J. Am. Stat. Assoc., 1958, 53, 457–481CrossRefGoogle Scholar
  36. [36]
    Cox D.R., Regression models and life tables., J. R. Stat. Soc. B., 1972, 34, 187–220Google Scholar
  37. [37]
    MacDonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction., N. Engl. J. Med., 2001, 345, 725–730PubMedCrossRefGoogle Scholar
  38. [38]
    Sato K., Tamura G., Tsuchiya T., Endoh Y., Usuba O., Kimura W., et al., Frequent loss of expression without sequence mutations of the gene in primary gastric cancer., Br. J. Cancer., 2001, 85(2), 199–203PubMedCrossRefGoogle Scholar
  39. [39]
    Johnston P.J., Lenz H.J., Leichman C.G., Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors., Cancer. Res., 1995, 55, 1407–1412PubMedGoogle Scholar
  40. [40]
    Edler D., Glimelius B., Hallstrom M., Jacobsen A., Johnston P.G., Magnuson I., et al., Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy., J. Clin. Oncol., 2002, 20, 1721–1728PubMedCrossRefGoogle Scholar
  41. [41]
    Schipper D.L., Wagenmans M.J.M., Peters W.H.M., Wagener D.J.T., Significance of cell proliferation measurement in gastric cancer., Eur. J. Cancer., 1998, 34, 781–790PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Aristotle Bamias
    • 1
  • George Fountzilas
    • 2
  • Michael Michael
    • 3
  • Christos Konstantaras
    • 2
  • Eleftheria Vrettou
    • 2
  • Efstathios Eleftheriadis
    • 4
  • Pavlos Papakostas
    • 5
  • Konstantionos Papadimitriou
    • 5
  • Nicholas Pavlidis
    • 1
  • Nikos Xiros
    • 6
  • Maria Bai
    • 3
  1. 1.Oncology DeptIoannina University HospitalIoanninaGreece
  2. 2.AHEPA HospitalAristotle University of ThessalonikiThessalonikiGreece
  3. 3.Histocytopathology LaboratoryIoannina University HospitalIoanninaGreece
  4. 4.Histocytopathology Laboratory for Social InsuranceThessalonikiGreece
  5. 5.Ippokration HospitalAthensGreece
  6. 6.Evangelismos HospitalAthensGreece

Personalised recommendations